Finch Therapeutics Group IncNASDAQ:FNCHNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE2.7888
- TODAY'S CHANGE (%)0.4788 (20.7273%)
- Bid / Lots2.4500/ 4
- Ask / Lots2.5600/ 11
- Open / Previous Close2.4500 / 2.3100
- Day Range
- 52 Week Range
- Volume693,546
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | FNCH |
|---|---|---|
| 09:32 ET | 8600 | 2.4575 |
| 09:34 ET | 300 | 2.5099 |
| 09:36 ET | 800 | 2.4575 |
| 09:38 ET | 800 | 2.51 |
| 09:39 ET | 1716 | 2.53 |
| 09:41 ET | 300 | 2.52 |
| 09:43 ET | 150 | 2.4118 |
| 09:45 ET | 5624 | 2.4801 |
| 09:48 ET | 6116 | 2.48 |
| 09:50 ET | 445 | 2.5048 |
| 09:52 ET | 3273 | 2.47 |
| 09:54 ET | 5156 | 2.48 |
| 09:56 ET | 830 | 2.5299 |
| 09:57 ET | 800 | 2.53 |
| 09:59 ET | 4679 | 2.495 |
| 10:03 ET | 600 | 2.495 |
| 10:06 ET | 2481 | 2.4705 |
| 10:08 ET | 300 | 2.46 |
| 10:12 ET | 500 | 2.505 |
| 10:14 ET | 1450 | 2.51 |
| 10:15 ET | 6030 | 2.47 |
| 10:19 ET | 600 | 2.41 |
| 10:21 ET | 121 | 2.41 |
| 10:24 ET | 2183 | 2.4 |
| 10:30 ET | 150 | 2.42 |
| 10:32 ET | 800 | 2.41 |
| 10:37 ET | 100 | 2.41 |
| 10:42 ET | 1500 | 2.42 |
| 10:51 ET | 1000 | 2.4864 |
| 10:53 ET | 500 | 2.4866 |
| 10:55 ET | 100 | 2.47 |
| 11:02 ET | 100 | 2.46 |
| 11:06 ET | 100 | 2.45 |
| 11:24 ET | 996 | 2.47 |
| 11:44 ET | 200 | 2.45 |
| 11:54 ET | 100 | 2.41 |
| 12:02 ET | 100 | 2.4101 |
| 12:20 ET | 400 | 2.48 |
| 12:30 ET | 500 | 2.4776 |
| 12:32 ET | 1100 | 2.455 |
| 12:34 ET | 7408 | 2.495 |
| 12:36 ET | 2877 | 2.553 |
| 12:39 ET | 2587 | 2.5304 |
| 12:48 ET | 1505 | 2.56 |
| 12:57 ET | 100 | 2.54 |
| 12:59 ET | 3200 | 2.56 |
| 01:01 ET | 500 | 2.5852 |
| 01:06 ET | 747 | 2.633 |
| 01:12 ET | 568 | 2.68 |
| 01:26 ET | 650 | 2.68 |
| 01:37 ET | 100 | 2.6001 |
| 01:39 ET | 200 | 2.64 |
| 01:50 ET | 100 | 2.64 |
| 01:51 ET | 500 | 2.6799 |
| 01:53 ET | 1500 | 2.6799 |
| 02:02 ET | 600 | 2.67 |
| 02:09 ET | 250 | 2.69 |
| 02:13 ET | 1200 | 2.655 |
| 02:15 ET | 500 | 2.69 |
| 02:22 ET | 100 | 2.69 |
| 02:26 ET | 18678 | 2.6834 |
| 02:27 ET | 34773 | 2.8525 |
| 02:29 ET | 9008 | 2.8899 |
| 02:31 ET | 9972 | 2.896 |
| 02:33 ET | 9400 | 2.6825 |
| 02:36 ET | 250 | 2.74 |
| 02:38 ET | 374 | 2.7792 |
| 02:40 ET | 1200 | 2.82 |
| 02:44 ET | 4097 | 2.77 |
| 02:45 ET | 8240 | 2.8951 |
| 02:47 ET | 16154 | 2.85 |
| 02:49 ET | 35287 | 2.9 |
| 02:51 ET | 12991 | 2.9112 |
| 02:54 ET | 8402 | 2.955 |
| 02:56 ET | 64055 | 2.8801 |
| 02:58 ET | 19761 | 2.955 |
| 03:00 ET | 14227 | 2.9 |
| 03:02 ET | 7321 | 2.88 |
| 03:03 ET | 7264 | 2.8 |
| 03:05 ET | 900 | 2.8 |
| 03:07 ET | 2900 | 2.7409 |
| 03:09 ET | 7877 | 2.59 |
| 03:12 ET | 2300 | 2.68 |
| 03:14 ET | 18041 | 2.69 |
| 03:16 ET | 1475 | 2.6301 |
| 03:18 ET | 1000 | 2.6003 |
| 03:20 ET | 1550 | 2.62 |
| 03:21 ET | 8625 | 2.69 |
| 03:23 ET | 10479 | 2.6301 |
| 03:25 ET | 2200 | 2.675 |
| 03:27 ET | 12477 | 2.6301 |
| 03:32 ET | 675 | 2.6628 |
| 03:34 ET | 3717 | 2.665 |
| 03:36 ET | 3200 | 2.68 |
| 03:38 ET | 1100 | 2.64 |
| 03:39 ET | 3100 | 2.698 |
| 03:43 ET | 5923 | 2.66 |
| 03:45 ET | 400 | 2.66 |
| 03:48 ET | 300 | 2.6683 |
| 03:50 ET | 200 | 2.64 |
| 03:52 ET | 200 | 2.65 |
| 03:54 ET | 800 | 2.7 |
| 03:56 ET | 2714 | 2.695 |
| 03:57 ET | 9565 | 2.79 |
| 03:59 ET | 16077 | 2.7888 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Finch Therapeutics Group Inc | 3.7M | -0.1x | --- |
Yield10 Bioscience Inc | 4.0M | -0.1x | --- |
Biophytis SA | 3.4M | -0.1x | --- |
Clearmind Medicine Inc | 3.8M | 0.0x | --- |
GeoVax Labs Inc | 3.6M | -0.1x | --- |
Axim Biotechnologies Inc | 3.5M | -0.3x | --- |
Company Information
Finch Therapeutics Group, Inc. is a microbiome technology company with a portfolio of intellectual property and microbiome assets. It is focused on realizing the value of its intellectual property estate and other assets, while supporting the advancement of its microbiome technology through partnerships and collaborations. It has an intellectual property estate, including more than 113 issued U.S. and foreign patents with relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. Its assets include CP101, an orally administered microbiome candidate designed for the prevention of recurrent C. difficile infection (CDI), with positive clinical data from a Phase II randomized, placebo-controlled trial and a Phase II open-label trial, and pre-clinical assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Additionally, it has also developed a biorepository of strains and samples.
Contact Information
- Headquarters
- 75 State Street, Suite 100BOSTON, MA, United States 02109
- Phone
- 617-229-6499
- Fax
- 302-636-5454
Executives
- Non-Executive Independent Chairman of the Board
- Susan Graf
- Chief Executive Officer
- Matthew Blischak
- Chief Financial Officer
- Lance Thibault
- Independent Director
- Domenic Ferrante
- Independent Director
- Christian Lange
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.7M |
|---|---|
Revenue (TTM) | $107.0K |
Shares Outstanding | 1.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-46.59 |
Book Value | $14.25 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 34.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -78,948.60% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
